SEHK:8225

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People’s Republic of China. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has China Health Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8225's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.8%

8225

-0.9%

HK Life Sciences

-0.7%

HK Market


1 Year Return

235.0%

8225

97.0%

HK Life Sciences

0.4%

HK Market

Return vs Industry: 8225 exceeded the Hong Kong Life Sciences industry which returned 95% over the past year.

Return vs Market: 8225 exceeded the Hong Kong Market which returned 1.4% over the past year.


Shareholder returns

8225IndustryMarket
7 Day-6.8%-0.9%-0.7%
30 Day-10.4%17.5%4.9%
90 Day-41.5%25.7%1.2%
1 Year235.0%235.0%97.0%97.0%4.6%0.4%
3 Year153.7%153.7%138.1%136.7%-7.1%-17.2%
5 Year27.8%27.8%128.3%122.5%15.0%-4.5%

Price Volatility Vs. Market

How volatile is China Health Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Health Group undervalued compared to its fair value and its price relative to the market?

8.66x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 8225 (HK$0.36) is trading above our estimate of fair value (HK$0.13)

Significantly Below Fair Value: 8225 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 8225 is good value based on its PE Ratio (9x) compared to the XA Life Sciences industry average (64.2x).

PE vs Market: 8225 is good value based on its PE Ratio (9x) compared to the Hong Kong market (11.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8225's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8225 is overvalued based on its PB Ratio (3.9x) compared to the HK Life Sciences industry average (3.7x).


Next Steps

Future Growth

How is China Health Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Health Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China Health Group performed over the past 5 years?

15.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8225 has a high level of non-cash earnings.

Growing Profit Margin: 8225's current net profit margins (46.5%) are higher than last year (40.2%).


Past Earnings Growth Analysis

Earnings Trend: 8225's earnings have grown by 15.5% per year over the past 5 years.

Accelerating Growth: 8225's earnings growth over the past year (43%) exceeds its 5-year average (15.5% per year).

Earnings vs Industry: 8225 earnings growth over the past year (43%) exceeded the Life Sciences industry 17.7%.


Return on Equity

High ROE: 8225's Return on Equity (43.5%) is considered outstanding.


Next Steps

Financial Health

How is China Health Group's financial position?


Financial Position Analysis

Short Term Liabilities: 8225's short term assets (CN¥128.3M) exceed its short term liabilities (CN¥51.4M).

Long Term Liabilities: 8225's short term assets (CN¥128.3M) exceed its long term liabilities (CN¥2.5M).


Debt to Equity History and Analysis

Debt Level: 8225's debt to equity ratio (1.9%) is considered satisfactory.

Reducing Debt: 8225 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: 8225's debt is well covered by operating cash flow (743.4%).

Interest Coverage: 8225's interest payments on its debt are well covered by EBIT (274.6x coverage).


Balance Sheet


Next Steps

Dividend

What is China Health Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8225's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8225's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8225's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8225's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8225's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

China Health Group has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Xia Guo
Chairmanno datano data46.62%
CN¥ 164.7m
Xuemei Song
Head of HR Mgmt Deptno dataCN¥99.00k-0.0077%
CN¥ -27.2k
Liang Li
Financial Director4.5yrsno datano data
Tuo Jin
Joint Chief Technology Officer and Member of Scientific Advisory Boardno datano datano data
Tarun Gupta
Co-Head of Business Development Department - International Divisionno datano datano data
Albert Qin
Chief Medical Officer4.5yrsno datano data
Yan Xing
Company Secretary1.58yrsno datano data
Yuen Ling Lam
Company Secretary & Authorized Representative0.75yrno datano data
Yiu Sun
Adviser for Medical Affairs and Member of Corporate Advisory Boardno datano datano data

4.5yrs

Average Tenure

55yo

Average Age

Experienced Management: 8225's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xia Guo
Chairmanno datano data46.62%
CN¥ 164.7m
Xuemei Song
Head of HR Mgmt Deptno dataCN¥99.00k-0.0077%
CN¥ -27.2k
Tuo Jin
Joint Chief Technology Officer and Member of Scientific Advisory Boardno datano datano data
Yiu Sun
Adviser for Medical Affairs and Member of Corporate Advisory Boardno datano datano data
Ye-Hong Zhang
Member of Corporate Advisory Boardno datano datano data
Vikash Salig
Member of Corporate Advisory Boardno datano datano data
Gengmin Xiao
Member of Corporate Advisory Boardno datano datano data
Chen Yan
Member of Scientific Advisory Boardno datano datano data
H. Lee
Member of Scientific Advisory Boardno datano datano data
Binghui Ni
Independent Non-Executive Director5.58yrsno datano data
Rui Qiu
Independent Non-Executive Director2.58yrsno datano data
Zhen Ling
Independent Non Executive Director2.25yrsno datano data

2.6yrs

Average Tenure

55yo

Average Age

Experienced Board: 8225's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Health Group Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Health Group Inc.
  • Ticker: 8225
  • Exchange: SEHK
  • Founded: 1998
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$353.350m
  • Shares outstanding: 995.35m
  • Website: https://www.chgi.net

Number of Employees


Location

  • China Health Group Inc.
  • Boda Building
  • 28 Beiqing Road
  • Beijing
  • 102200
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
8225SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJul 2003

Biography

China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People’s Republic of China. The company offers contracted cl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/29 12:33
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.